Isfahan University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Application of Cell Free Dna in Art Publisher Pubmed



Alizadegan A1 ; Dianatmoghadam H2 ; Shadman N3 ; Nouri M1 ; Hamdi K1 ; Ghasemzadeh A1 ; Akbarzadeh M4 ; Sarvarian P5 ; Mehdizadeh A6 ; Dolati S7 ; Yousefi M5, 8
Authors
Show Affiliations
Authors Affiliations
  1. 1. Department of Reproductive Biology, Faculty of Advanced Medical Sciences, Tabriz University of Medical Sciences, Tabriz, Iran
  2. 2. Department of Genetics and Molecular Biology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran
  3. 3. Department of Midwifery, Kazerun Branch, Islamic Azad University, Kazerun, Iran
  4. 4. Laboratory Science Expert, Infertility Ward, Al-zahra Hospital, Tabriz, Iran
  5. 5. Stem Cell Research Center, Tabriz University of Medical Sciences, Tabriz, Iran
  6. 6. Hematology and Oncology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran
  7. 7. Physical Medicine and Rehabilitation Research Center, Aging Research Institute, Tabriz University of Medical Sciences, Tabriz, Iran
  8. 8. Department of Immunology, Faculty of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran

Source: Placenta Published:2022


Abstract

Various biopsy and sampling methods are used for preimplantation genetic diagnosis (PGD) of embryo. This method benefits blastomer/trophectoderm biopsy to improve the clinical outcome of in vitro fertilization (IVF). However, all of these procedures are invasive and have adverse effects on embryo development. Additionally, these procedures require expensive equipment and well-experienced technicians. Regarding these limitations, designing non-invasive methods is necessary. One of the recently proposed non-invasive and applicable methods is cell free DNA (cfDNA) molecule evaluation that have opened up exciting opportunities in the molecular diagnosis of embryo and fetus chromosomal aneuploidy. cfDNA is present in body fluids; especially blood, follicular fluid, amniotic fluid, spent embryo culture medium (SCM) and blastocoel fluid. Overall, this review highlights the cfDNA biomarker might constitute a supplemental tool for improving IVF and pregnancy outcomes, female infertility management. However, the successful application of cfDNA demands an understanding of its biological properties, kinetics, time of collection, high sensitivity and specificity cfDNA detection methods, and their limitation and challenges in the clinical settings. In this review we also describe ethical aspects of cfDNA testing. © 2022 Elsevier Ltd
Related Docs
1. Isolation of Cfdna From Spent Culture Media and Its Association With Implantation Rate and Maternal Immunomodulation, BMC Research Notes (2022)
2. Down Syndrome: Current Status, Challenges and Future Perspectives, International Journal of Molecular and Cellular Medicine (2016)
3. Fetal Nucleic Acids in Maternal Circulation for Noninvasive Prenatal Diagnosis, Journal of Isfahan Medical School (2016)
4. Diagnosis of Echinococcosis by Detecting Circulating Cell-Free Dna and Mirna, Expert Review of Molecular Diagnostics (2023)
5. Detection of Paternally Inherited Fetal Point Mutations for Β-Thalassemia in Maternal Plasma Using Simple Fetal Dna Enrichment Protocol With or Without Whole Genome Amplification: An Accuracy Assessment, Journal of Maternal-Fetal and Neonatal Medicine (2016)
Experts (# of related papers)
View all Related Experts
Rasoul Salehi (2)
Mohammad Kazemi (1)